Follow the Pundits

Tag: Illumina deal

Colorful illustration of a biotech laboratory bench where giant dollar bills swirl around proteomics and genomics machines, while a cartoon Casdin Capital scientist eagerly drops more LAB-branded test tubes into a glowing investment beaker.

Biotech Venture Capital Firm Casdin Keeps Buying Standard BioTools Shares — Time To Invest, Or Time To Label This “Highly Experimental”?

Casdin Capital just scooped up over a million shares of Standard BioTools — again. With strong tech, big cash coming from Illumina, and a major restructuring underway, is this small-cap biotech tools maker a deep-value setup or just another “high-risk, high-lab-cost” gamble? Here’s what’s really going on.

Read entire article

Tags: Biotech Investing, Buy or Sell Lab Stock, Casdin Capital, featured-hedge-funds, FUNanc1al, Funanc1al Edge, genomics, Illumina deal, insider activity, institutional buying, LAB stock, life sciences tools, proteomics, Risks Investing LAB Stock, small-cap stocks, spatial biology, speculative investing, standard biotools, turnaround plays, Why Buy LAB Stock